GleamWall
中文EN

NMAD NOMAD POWER SOLUTIONS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1335105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-474.2%
TTM EPS YoY-283.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-39.2%
ROA-31.9%
ROIC (approx.)-35.2%
Asset turnover—

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.00x
Current ratio0.78x
Interest coverage-191.93x

Cash quality & payout

Operating cash flow / net income0.46x
Accruals ratio-17.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$472,000———$652,000———
Cost of revenue$470,000———$539,000———
Gross profit$2,000———$113,000———
R&D expense$473,000$62,250$333,376$52,118$31,000$60,648$91,457$34,830
SG&A expense$9.20M$2.29M$1.65M$1.77M$1.17M$714,161$615,483$1.94M
Operating income-$15.09M-$2.35M-$1.99M-$1.82M-$1.09M-$774,809-$706,940-$613,497
Interest expense$103,000$851$3,096$3,756$352,000$1,810$3,135$4,432
Net income-$13.64M-$2.19M-$1.92M-$2.61M-$1.44M-$775,673-$709,555-$617,694
EPS (basic)-0.74-0.16-0.18—-1.30-0.29-0.29—
EPS (diluted)-0.74-0.16-0.18—-1.30-0.29-0.29—
Weighted avg. shares (diluted)18.43M13.48M10.89M—1.11M2.72M2.47M—
Balance sheet
Cash & equivalents$5.65M$12.67M$3.25M$156,000$2.89M$887,212$1.38M$1.04M
Receivables$503,000——$529,000————
Inventory$6.43M——$6.67M————
Current assets$17.05M$19.30M$3.41M$8.39M$5.43M$989,752—$1.15M
PP&E, net$455,000$6.61M$6.61M$474,000————
Goodwill$94.34M———————
Intangibles$171,000——$147,000————
Total assets$122.07M$26.65M$10.87M$11.91M$5.43M$1.19M$1.51M$1.15M
Current liabilities$21.82M$1.50M$1.22M$18.05M$521,422$537,122$355,098$318,284
Short-term debt$5.76M——$1.14M————
Long-term debt———$5.47M————
Total debt———$6.61M————
Total liabilities$21.91M$1.66M$1.69M$23.66M$14.37M$8.84M$355,098$318,284
Shareholders' equity$99.08M$23.91M$7.95M-$11.75M$4.91M$651,456$1.16M$827,219
Net debt———$6.45M————
Shares outstanding18.23M15.42M11.63M1.11M5.70M2.76M2.68M2.25M
Cash flow statement
Operating cash flow-$4.85M-$1.61M-$1.83M-$1.09M-$926,752-$487,485-$568,483-$598,675
Investing cash flow$19.15M-$6.50M-$24,859-$535,102————
Financing cash flow-$16.37M——$3.84M$5.56M-$10,000$914,228—
Stock-based compensation—$622,614$82,176$243,974$776,611$240,499$99,738$77,977

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.